Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 31 | 2025Novo, Lilly, and AZ Data at ACC 2025; Vertex T1DM Updates; Palatin Ph2 Obesity Results; Noom Integrates with LillyDirect; SAB Q4 ‘24 Earnings Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 28 | 2025Novo Buys Oral Obesity Asset from Lexicon; Corbus Ph1 CB1 Trial Update Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 26 | 2025Metsera and Beta Bionics Q4 ’24 Earnings; Viking Oral GLP-1RA Ph2 Trial Update; Vivani Preclinical Data; Dexcom Appoints New CCO Purchase Blast
$599
Posted in: Other, Topics Mar 25 | 2025Merck Enters Licensing Agreement for Oral Lp(a)Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 24 | 2025Novo Buys Triple Agonist and Expands Wegovy Savings Program; Biomea Presents Data at ATTD 2025; March CHMP AgendaPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 21 | 2025ATTD 2025 Key Press Releases (March 21) Purchase Blast$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 21 | 2025ATTD 2025 Key Press Releases (March 20) Purchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 19 | 2025ATTD 2025 Key Press Releases (March 19)Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 18 | 2025CMS Price Negotiation Update; Ypsomed and CamDiab Launch mylife Loop on iOSPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 17 | 2025Bayer’s Finerenone Under Priority Review; Dexcom Receives FDA Warning; Zealand Completes Petrelintide Ph2b Enrollment; vTv Announces Clinical Hold Lift; Entera/OPKO Advance Oral AOM to ClinicPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 17 | 2025Obesity Spotlight: Can BI Step Outside of Lilly's Shadow?Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 14 | 2025Altimmune R&D Day 2025; Sagimet Q4 ‘24 Earnings Update; Ascletis Ph1b Data Readout; Fauna Bio Series A for HFpEFPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA + Basal, Other, Topics Mar 12 | 2025Roche is a Zeal-ot for PetrelintidePurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 11 | 2025Obesity Compounders Take a Hit; Viking Signs Manufacturing Deal; Roche Hires Novo Exec; Halia Receives Novo’s Golden TicketPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, Topics Mar 10 | 2025Cagrisema T2DM + Obesity Ph3 Results; BI Discontinues MASH Asset; Mineralys Releases New HTN Results; Insulet SmartAdjust 2.0 Trial ObservedPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 10 | 2025Obesity Spotlight: Zealand’s Path to Find a PartnerPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Mar 06 | 2025Amgen Initiates Ph3 MariTide Trials; LifeMD and Teladoc Integrate with LillyDirect; Arrowhead Preclinical Obesity DataPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 06 | 2025Novo Launches NovoCare DTP Platform; Lilly Manufacturing Pitches from States and Initiates TRIUMPH-6Purchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Mar 04 | 2025New Lilly TV Ad; Novo Updates Ozempic Promo Campaign; Senseonics, Fractyl, and Esperion Q4 ‘24 Earnings UpdatesPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Mar 04 | 2025AbbVie Enters Obesity Race; Novo Initiates New Drug Development AI Partnership; Biocon Launches Generic Liraglutide in UKPurchase Blast